Metastatic Hormone-Sensitive Prostate Cancer
Conditions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: - Asymptomatic or mildly symptomatic, histologically-confirmed de novo metastatic hormone-sensitive prostate adenocarcinoma without small-cell tumours - Consent to provide a FFPE tissue block (preferred) or slides. Tissue from bone metastases is not acceptable - A valid PTEN IHC result indicating PTEN deficiency (centralized testing) - Metastatic disease documented prior to randomisation by clear evidence of = 1 bone lesion and/or = 1 soft tissue lesion accurately assessed at baseline and suitable for repeated assessment with CT and/or MRI. PSMA PET identification only will not be eligible - Candidate for abiraterone and steroid therapy - Ongoing ADT with GnRH analogue, or LHRH agonists or antagonist, or bilateral orchiectomy - Eastern Cooperative Oncology Group (ECOG)/WHO performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks - Able and willing to swallow and retain oral medication - 7-day Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory(BFI) questionnaires and the analgesic diary during screening completed - Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 600 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 400
Exclusion criteria
Exclusion criteria: -Radiotherapy with a wide field of radiation within 4 weeks(wks) before start of study treatment (capivasertib/placebo) -Major surgery (excl.placement of vascular access,transurethral resection of prostate,bilateral orchiectomy,internal stents) within 4 wks of start of study treatment -Brain metastases,or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring steroids for at least 4 wks prior to start of study treatment) -Past medical history of interstitial lung disease,drug-induced interstitial lung disease,radiation pneumonitis which required steroid treatment,or any evidence of clinically active interstitial lung disease -Any of the following cardiac criteria: i.Mean resting corrected QT interval (QTc) >470 msec from triplicate ECGs ii.Any clinically important abnormalities in conduction or morphology of resting ECG iii.Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalaemia,potential for torsades de pointes,congenital long QT syndrome or any concomitant medication known to prolong the QT interval iv.Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft,angioplasty,myocardial infarction, or unstable angina pectoris. v.Congestive heart failure New York Heart Association (NYHA)Grade =2 vi.Symptomatic hypotension - systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg vii.Uncontrolled hypertension (SBP =160 mmHg or DBP =95 mmHg). -Clinically significant abnormalities of glucose metabolism as defined by any of the following: i.Patients with diabetes mellitus (DS) type 1 or DS type 2 requiring insulin treatment ii.HbA1c =8.0% (63.9 mmol/mol) -Inadequate bone marrow reserve or organ function -As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses,or known active infection including hepatitis B and C,and HIV -Unevaluable for both bone and soft tissue progression as defined by meeting both of the following criteria: i.a "superscan" of bone scan,and ii.no soft tissue lesion that can be assessed by RECIST criteria -Refractory nausea and vomiting, malabsorption syndrome,chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection,or other condition that would preclude adequate absorption of capivasertib -Any other disease,metabolic dysfunction,physical examination finding,or clinical laboratory finding that,in the investigator’s opinion,gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug,may affect the interpretation of the results,render the patient at high risk from treatment complications or interferes with obtaining informed consent -Evidence of dementia,altered mental status,or any psychiatric condition that would prohibit understanding or rendering of informed consent -Previous allogeneic bone marrow transplant or solid organ transplant -History of another primary malignancy except for malignancy treated with curative intent with no known disease = 2 years. before the first dose of study intervention and of low potential risk for recurrence.Exceptions include adequately resected non-melanoma cancer and curatively treated in situ disease. -Treatment with any of the following: i.Nitrosourea or mitomycin C within 6 wks of the start of study treatment ii.Any investigational
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone assessment by the investigator of radiographic progression-free survival (rPFS) in patients with PTEN-deficient mHSPC;Secondary Objective: 1.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of overall survival 2.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to start of first subsequent therapy or death (TFST) 3.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to start symptomatic skeletal event-free survival (SSE-FS) 4.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to pain progression (TTPP) 5.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to PSA progression 6.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of progression-free survival after next-line treatment (PFS2) 7.To evaluate the PK of capivasertib in combination with abiraterone;Primary end point(s): 1.Radiographic Progression-free Survival (rPFS) in patients with PTEN-deficient Per Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST 1.1) for soft tissue and/or Prostate Cancer Working Group 3(PCWG3) for bone as Assessed by the Investigator;Timepoint(s) of evaluation of this end point: 1.The time from randomisation to: 1) radiographic progression, as assessed by the investigator per RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), or 2) death due to any cause | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of overall survival 2.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to start of first subsequent therapy or death (TFST) 3.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to start symptomatic skeletal event-free survival (SSE-FS) 4.To compare the effect of capivasertib+abiraterone relative to placebo+abiraterone by assessment of time to pain progression (TTPP) 5.To evaluate the PK of capivasertib in combination with abiraterone 6.To evaluate safety and tolerability assessment of capivasertib+abiraterone as compared to placebo+abiraterone in patients with PTEN-deficient mHSPC;Timepoint(s) of evaluation of this end point: 1.Time from randomisation until the date of death due to any cause 2.Time from randomisation to the earlier of:the start date of the first subsequent anticancer therapy,or death due to any cause 3.The time from randomisation until:use of radiation therapy to prevent or relieve skeletal symptoms; Occurrence of new symptomatic pathological bone fractures; Occurrence of spinal cord compression; Orthopaedic surgical intervention for bone metastasis; Death due to any cause 4.Time from randomisation to clinically meaningful pain progression (2-points) increase from baseline BPI-SF and/or initiation of/increase in the analgesic use 5.Pre-dose and post-dose(1h and 4h) 6.The overall duration of the study | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Czech Republic, France, Germany, Hong Kong, India, Israel, Japan, Korea, Republic of, Mexico, Netherlands, Peru, Philippines, Poland, Russian Federation, Slovakia, South Africa, Spain, Taiwan, Thailand, Türkiye, United Kingdom, United States, Viet Nam
Contacts
Public ContactInformation Center
AstraZeneca
Outcome results
None listed